Tecovirimat — an antiviral drug to treat monkeypox
Since May 2022, monkeypox has been spreading in Canada and other countries. Strikingly, the vast majority of people who have become ill with monkeypox are gay, bisexual and other men who have sex with men. Doctors in Canada are hard at work trying to further understand its spread, how it causes illness and ways to prevent and treat it.
Although a vaccine and an antiviral drug called tecovirimat, or Tpoxx, are approved in Canada for the prevention and treatment of monkeypox, they have not been widely studied. Furthermore, supplies of both the vaccine and antiviral drug are limited.
While new diagnoses of monkeypox are lower than they were a few months ago, monkeypox is unlikely to disappear. Therefore, research on monkeypox needs to intensify and continue.
Professor Sharon Walmsley, MD, is one of North America’s leading infectious disease specialists, based at the Toronto General Hospital. She has been caring for people with monkeypox and has published her findings in leading medical journals.
In this webinar, Dr. Walmsley will be discussing tecovirimat and why a clinical trial is needed. She will provide a brief overview of the monkeypox outbreak in Canada, and will talk about a clinical trial that she and colleagues at McGill University are undertaking.
Moderator: Sean Hosein, Science and Medicine Editor, CATIE
Speaker: Sharon Walmsley, MD, Toronto General Hospital, University of Toronto
This webinar will be presented in English with simultaneous interpretation in French. Due to the time-sensitive nature of the content, presentation slides will be translated into French and shared after the webinar.